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SHORT COMMUNICATION
Decrease of cartilage transforming growth factor-b receptor II
expression in the rabbit experimental osteoarthritis—potential role
in cartilage breakdown
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Introduction
Osteoarthritis (OA) is characterized by cartilage
destruction in which the cytokine interleukin-1
(IL-1) plays a central role, by its ability to induce
expression of cartilage degrading enzymes and to
depress the synthesis of major matrix components
[1–4]. Interestingly, it has been reported that OA
chondrocytes are hyper-responsive to stimulation
by IL-1 and display upregulation of IL-1 receptor
[5].
However, OA animal models have revealed an
activation of chondrocytes and enhanced proteo-
glycan (PG) synthesis in early stages of the process
[6, 7], and even at late stages of OA, the remaining
chondrocytes quite often show enhanced PG
synthesis, as if they were attempting to replenish
the depleted matrix. Among the local growth
factors that could be involved in this repair
potentiality, TGF-b (transforming growth factor-b)
may play a pivotal role as it has been shown to
enhance matrix production and to modulate cell
proliferation [reviewed in 8]. TGF-b can also
counter the IL-1-induced effects on expression of
metalloproteases and matrix molecules and down-
regulate the expression of IL-1 receptor in
articular chondrocytes [8]. Furthermore, repeated
intra-articular injections of TGF-b in the murine
knee joint caused upregulation of chondrocyte PG
synthesis and development of osteophytes [9].
Articular chondrocytes express at least the three
major TGF-b receptors, type I, type II and type III
(betaglycan). It is now established that only types
I and II are implicated in the signal transduction.
TGF-b binds to type II receptor and then forms an
heterotrimer with type I which is transphophory-
lated and transmits the signal through a serine-
threonine kinase mechanism [10].
So far, it is not known if the expression of TGF-b
and its receptors is altered in osteoarthritic
cartilage. Our hypothesis was that changes in
TGF-b expression could explain the enhanced
metabolic activity of OA cartilage, as well as the
decreased metabolic activity of the tissue observed
at the end stage of cartilage destruction [7].
Cruciate ligament section in the rabbit knee is
known to induce an initial stage of joint
hypertrophy including an increased cartilage
thickness and lately a stage of cartilage destruc-
tion similar to that observed in OA human joint at
the time of joint replacement [6, 7]. Thus, the model
allows the study of factors regulating both the
repair and the destruction of articular cartilage.
Here we show that the expression of TGF-b1 and
TGF-b2 was slightly decreased in advanced stages
of the rabbit OA (fibrillated cartilage) whereas the
message for TGF-b receptor II was dramatically
reduced as early as the hypertrophic stage. These
alterations could result in the reduced sensivity of
articular chondrocytes to TGF-b during develop-
ment of the osteoarthritic process. This would
explain, at least partially, that repair potential of
cartilage becomes progressively unable to balance
the erosive process.
Methods
Twenty-five male rabbits (1.8–2.0 kg), were
subjected to transection of either the anterior
cruciate ligament (ACL) or of both the ACL and
the posterior cruciate ligament (PCL) [7]. Both
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knees of the same animal were subjected to the
same surgery. The animals were divided into (1) a
‘control group’ of five unoperated animals which
were killed 4 weeks later, (2) an ‘early’ group of five
rabbits with section of the ACL ligaments and
were killed 1 week after surgery, (3) an ‘hyper-
trophic’ group of six rabbits with section of the
ACL and killed after 4 weeks, (4) a ‘late’ group of
nine animals which had section of both cruciate
ligaments and were killed 8 weeks after surgery.
Each of the six articular surfaces of the knee
joint (patella, femoral groove, medial and lateral
femoral condyles, medial and lateral tibial
plateaux) was examined with a magnifying-glass
and graded as follow: 0 = normal, 1 = hypertrophic
cartilage with intact surface and osteophytes;
2 = grade 1 + roughening or minimal fibrillation of
the articular surface; 3 = grade 1 + a region of deep
cartilage erosion; 4 = grade 1 + a small area of bone
exposure; 5 = large area of bone exposure (total
score range: 0–30). Only the grossly normal
cartilage of both the early and hypertrophic groups
was collected and fibrillated areas were carefully
avoided. Inversely, only the fibrillated cartilage of
the late group was collected while the remaining
normal cartilage was excluded. Cartilage slices
were frozen into liquid nitrogen and stored at
−70°C. The samples were subsequently pulverized
into powder in the presence of liquid nitrogen and
total RNA was then extracted (RNAXEL protocol,
Eurobio, France). To avoid interference with
aggrecans, the extracts were further purified in a
4-ml cushion of 5.6 m CsCl, by centrifugation for
24 h at 32 000 rpm and 18°C (Beckman SW 41 Ti
rotor). The concentration of RNA was determined
by measuring the OD260. The OD260/OD280 ratios
were greater than 1.8.
Total RNA (0.1 mg) was reverse transcribed into
cDNA according to the Life Technologies PCR kit
instructions. The reaction was performed at 42°C
for 1 h. Amplification of generated cDNA was
performed in an Omni E Hybaid thermocycler with
specific primers of TGF-b1, TGF-b2, TbR-I, TbR-II
and b-actin. Thirty-five cycles were chosen as the
appropriate number deduced from preliminary
amplification curves, with the following con-
ditions: 95°C, 30 s/55°C, 30 s/72°C, 1 min. Then, an
additionnal step at 72°C for 10 min was included.
Products were analyzed on a 2% agarose electro-
phoresis gel, using ethidium bromide staining, and
photographied with 665 Polaroid film. The specifi-
city of the transcripts was verified by Southern
blotting using human cDNA probes. Bands were
quantified by densitometric scanning (Image-
QuaNt software, Molecular Dynamics) and nor-
malized to b-actin expression.
Results/Discussion
In this study, special attention was paid to the
sampling method, taking care to collect only small
areas of normal and hypertrophic cartilage and
leaving apart the fibrillated zone in the first two
groups of operated animals and inversely taking
only fibrillated areas in the last group. This
approach permits to isolate well-defined cartilage
states but it has the disadvantage of material
scarcity so that the samples from the same group
of animals must be pooled. However, a preliminary
experiment revealed that the variation between
animals was low and did not cause unacceptable
scatter. RNA levels were sufficient to allow
semi-quantitative analysis of four to six different
genes and competitive PCR could not be applied as
it requires at least five-times as much RNA. In our
experiments the expression of actin was included
in all the assays as a reference gene and its
expression proved to be approximately constant in
all the samples. Furthermore, the differences
observed in the messages, specially in the case of
receptor II were so large that precise quantifi-
cation by competitive PCR would have been of
limited additional value.
We found that both the mRNA levels for TGF-b1
and TGF-b2 were significantly decreased in late
stages of OA, i.e., in cartilage samples showing
evidence of destructive lesions [Fig. 1(a) and 1(b)].
Moreover, at this time and in the earlier
hypertrophic stage, the expression of receptor type
II was dramatically reduced to almost undetect-
able levels. Given that TbR-II is absolutely
required to bind TGF-b, form an heteromeric
complex with TbR-I and transmit the signal [10],
we may suggest that this down-regulation results
in reduced sensitivity of the articular chondro-
cytes to TGF-b during development of the
osteoarthritic process. That the responsiveness of
OA chondrocytes diminishes would explain, at
least partially, that repair potential of altered
cartilage is no longer capable of balancing the
erosive process and that unreversible degradation
takes place.
It may seem surprising that down-regulation of
the TbR-II expression was observed as early as the
hypertrophic stage of the OA process, a time phase
where the chondrocytes are metabolically more
active, as it has been reported that cartilage from
OA lesions shows immediate sensitivity to TGF-b
and a greater stimulation of PG synthesis than
normal cartilage [11]. However, the hyperactivity
of chondrocytes during the hypertrophic phase
may result from a previous exposure to TGF-b
























































































Fig. 1. Semiquantitative analysis of TGF-b and receptor mRNA levels. RT-PCR reactions were performed using the
following primers: TGF-b1: sense 5'-GCCCTGGACACCAACTATTGC-3', antisense 5'-GCTGCACTTGCA-GGAGGGCAC-
3'; TGF-b2: sense 5'-GCTTTGGATGCGGCCTATTGC-3', antisense 5'-GCTGCATTTGCAAGACTTTAC-3'; TbR-I: sense
5'-CTGCTCCCGGGGGCGACGGCGTTACAGTGTTTCTGC-3', antisense 5'-TAAGTCTGCAATACAGCAAGTTC-
CATTCTT-3';TbR-II: sense 5'-CGCTTTGCTGAGGTCTATAAGGCC-3', antisense 5'-GATATTGGAGCTCTTGAGGTC-
CCT-3'; b-actin: sense 5'-GTGGGGCGCCCCAGGCACCA-3', antisense 5'-CTCCTTAATGTCACGCACGATTTC-3'. (a)
Ethidium bromide staining; (b) Densitometric scanning of the signals, normalized to b-actin expression. (c) Control
(unoperated rabbits). 1, Early stage of OA (1 week after section of cruciate ligaments). 2 and 3, Two different batches
of hypertrophic stage (4 weeks after section). The amount of material being greater at this stage, two pools of three
samples each were studied separately. 4, Late stage, fibrillated cartilage (8 weeks after section).
would also be possible that cartilage samples were
collected at the end of the hypertrophic stage, at
a transient stage in which cartilage would no
longer be able to produce TGF-b. This stage of
cartilage repair failure would be responsible for
the final destruction of the tissue. Work is in
progress to monitor the expression of aggrecan in
parallel to that of TGF-b and its receptors in the
same experimental OA model as an attempt to
clarify this point.
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The altered expression of TGF-b receptor types
may have profound consequences on the function-
nal activity of the chondrocytes and the properties
of cartilage matrix. Evidences have been recently
provided that the ratio of type I to type II receptors
modulates responsiveness to TGF-b in several cell
types, including chondrocytes [12–14]. Interest-
ingly, we previously demonstrated that rabbit
articular chondrocytes in culture express different
affinity for TGF-b1 as a function of the cell-cycle
phases [8, 14]. Recently, we could provide evidence
that the ratio of type I to type II receptor expression
levels decreased in S-phase chondrocytes, compared
to G0/G1 cells, as a result of down-regulation of type
I (Boumediene et al., in preparation). Therefore,
differential phenotype of TGF-b receptors may play
a great role in the proliferation of articular
chondrocytes in OA since we know that after the
initial cartilage lesion these cells leave their
quiescent state and start proliferate to form clones.
This stimulus may at this time induce the quiescent
chondrocytes to express a receptor profile that
predisposes them to be stimulated by TGF-b and
proliferate or that facilitates the activation by other
growth factor such as BMPs. Later on, there could
be changes in this profile as the disease progresses
and chondrocytes become less active.
In addition to transcriptional controls, several
potential mechanisms may control the availability
and biological effects of TGF-b molecules in the
cartilage: processing and activation of precursors,
interaction with other cell-surface binding proteins
including betaglycan and specific binding to matrix
components such as decorin and biglycan. To this
respect, it is of interest that the synthesis of
cartilage small dermatan sulfate proteoglycans
(decorin, biglycan and fibromodulin) is increased in
the hypertrophic phase of canine experimental OA
[15].
Despite that our findings are preliminary and
based on a single model, they suggest that new
perspectives in OA treatment should therefore tend
to stimulate the expression of TGF-bs and their
receptors in articular cartilage.
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